Publisher of the most cited open-access journals in their fields.
Frontiers in Cardiovascular Medicine is a global, peer-reviewed Open Access medical journal providing unrestricted, online access to publications on diagnostic and therapeutic advances in cardiology and cardiovascular disease. Frontiers in Cardiovascular Medicine publishes peer-reviewed scientific investigations of the highest quality that are of relevance for the diagnosis, treatment, or pathogenesis of cardiovascular disease and related disorders with the goal to understand disease processes and to improve medical practice and patient care.
The specialty section Cardiovascular Therapeutics aims to advance the pharmacological treatment of cardiovascular disease. The section is concerned will all aspects of drug discovery and development, improving our understanding of how and why drugs work, and tailoring medicines to individuals. The main emphasis of the section is on clinical studies in humans, either volunteers or patients. Articles concerning all phases of classical drug development are welcome, but not those that are simple pharmacokinetic equivalence studies.
We particularly welcome early phase translational trials, and experimental medicine studies where drugs are used to probe physiology or pathophysiology. Such articles may also include novel experimental approaches, and their validation. The section Cardiovascular Therapeutics is also concerned with the identification and validation of biomarkers to either aid drug development, or allow a stratified medicine approach in patients. Biomarkers may relate to physiological measures, genetics, or any of the emerging –omics technologies.
Although the section Cardiovascular Therapeutics is primarily concerned with human studies and clinical trials, proof-of-concept studies in animals which provide clear support for translation into humans are welcome. The central goal of Cardiovascular Therapeutics is to translate the wealth of pre-clinical knowledge about cardiovascular disease into pharmacological benefit for patients.
Authors should provide a cover letter along with their manuscript outlining what is novel about their work, and why it matters to patients. We also request that prospective organizers of Research Topics in Cardiovascular Therapeutics provide the Editorial Office with their CV, and clarify in the proposal how their research expertise qualifies them to organize a Research Topic on that particular subject.
The Editors of Frontiers in Cardiovascular Medicine encourage submission of Original Research Articles (clinical or preclinical), Reviews, Mini Reviews and Case Reports. Original research articles include manuscripts reporting results from clinical investigations, including Phase I-III trials and population studies. Reports from experimental studies from related areas such as physiology, pathophysiology, cellular and molecular biology, genetics, or pharmacology may be considered as as long as they relate to new understandings of pathogenic mechanisms or novel therapeutic approaches relevant to human disease. Articles related to medical education or the future development of medicine may also be considered.
Indexed in: PubMed, PubMed Central, Google Scholar, DOAJ
PMCID: all published articles receive a PMCID
Cardiovascular Therapeutics welcomes submissions of the following article types: Case Report, Clinical Study Protocol, Correction, Editorial, General Commentary, Hypothesis & Theory, Mini Review, Opinion, Original Research, Perspective, Review and Systematic Review.
All manuscripts must be submitted directly to the section Cardiovascular Therapeutics, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Articles published in the section Cardiovascular Therapeutics will benefit from the Frontiers impact and tiering system after online publication. Authors of published original research with the highest impact, as judged democratically by the readers, will be invited by the Chief Editor to write a Frontiers Focused Review - a tier-climbing article. This is referred to as "democratic tiering". The author selection is based on article impact analytics of original research published in all Frontiers specialty journals and sections. Focused Reviews are centered on the original discovery, place it into a broader context, and aim to address the wider community across all of Cardiovascular Medicine.